{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-286419","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.562824+00:00","generated_at":"2026-05-16T18:45:38.076541+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TuHURA provides pro forma statements for Kineta merger, closed June 30, 2025","bullets":["Pro forma combined statements for nine months ended Sept 30, 2025 and year ended Dec 31, 2024.","Kineta acquisition accounted for as business combination; TuHURA as acquirer with 92.4% ownership post-merger.","Pro forma adjustments eliminate pre-merger intercompany transactions and financing costs.","TuHURA advancing Kineta's VISTA-101 trial; REM-001 study underway with CVR milestone by Dec 31, 2025.","Historical financials of TuHURA remain the consolidated financial statements post-merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-286419","json":"https://secwatch.observer/filing/0001193125-25-286419.json","markdown":"https://secwatch.observer/filing/0001193125-25-286419.md","text":"https://secwatch.observer/filing/0001193125-25-286419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/0001193125-25-286419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/d851083d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:45:38.076541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}